Buscar resultados de ensayos clínicos
Lymphoma, T-Cell, Cutaneous - 27 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-09-09 Intervenciones:
|
Completed |
Nombre del estudio: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-11-29 Intervenciones: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
Nombre del estudio: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2002-08-08 Intervenciones:
|
Completed |
Nombre del estudio: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2005-09-13 Intervenciones: Drug: ONTAK (denileukin difitox, DAB389IL-2) |
No longer available |
Nombre del estudio: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2007-01-05 Intervenciones: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |
No longer available |
Nombre del estudio: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma Condición: Cutaneous T Cell Lymphoma Fecha: 2010-05-25 Intervenciones: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Recruiting |
Nombre del estudio: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Condición: Cutaneous T Cell Lymphoma Fecha: 2014-07-10 Intervenciones: Drug: Micro needle array-Doxorubicin (MNA-D) MNA-D patches will be applied to 3-4 CTCL skin patches or p |
Completed |
Nombre del estudio: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma Condición: Cutaneous T-Cell Lymphoma Fecha: 2007-01-22 Intervenciones: Drug: Panobinostat Other Name: LBH589 |
Withdrawn |
Nombre del estudio: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients Condición: Cutaneous T-cell Lymphoma Fecha: 2009-08-27 Intervenciones:
|
Completed |
Nombre del estudio: A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma Condición: Cutaneous T-cell Lymphoma Fecha: 2007-02-05 Intervenciones: Drug: APO866 APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 we |